Endothelial transdifferentiation in hepatocellular carcinoma: Loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival

Liver International

Volumn 33, Issue 9, 2013, Pages 1428-1440

  Géraud, Cyrill ^a   Mogler, Carolin ^c   Runge, Anja ^b   Evdokimov, Konstantin ^a   Lu, Shun ^a   Schledzewski, Kai ^a   Arnold, Bernd ^d   Hämmerling, Günter ^d   Koch, Philipp S ^a   Breuhahn, Kai ^c   Longerich, Thomas ^c   Marx, Alexander ^a   Weiss, Christel ^b   Damm, Friederike ^a   Schmieder, Astrid ^a   Schirmacher, Peter ^c   Augustin, Hellmut G ^b   Goerdt, Sergij ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CD32; Hepatocellular carcinoma; LSEC; Lyve 1; Sinusoidal endothelial cell; Stabilin; Tumour endothelium

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; FC RECEPTOR IIB; LYVE 1 PROTEIN; MEMBRANE PROTEIN; PROTEIN; STABILIN 1; STABILIN 2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CELL ADHESION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; CORRELATIONAL STUDY; ENDOTHELIUM CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER NODULE; LIVER SINUSOID; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CD32; HEPATOCELLULAR CARCINOMA; LSEC; LYVE-1; SINUSOIDAL ENDOTHELIAL CELL; STABILIN; TUMOUR ENDOTHELIUM;

ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES, NEURONAL; CELL TRANSDIFFERENTIATION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICROARRAY ANALYSIS; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, IGG; RECEPTORS, LYMPHOCYTE HOMING; VESICULAR TRANSPORT PROTEINS;

EID: 84883795741     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12262     Document Type: Article

References (59)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Sakamoto M. Early HCC: diagnosis and molecular markers. J Gastroenterol 2009; 44: 108-11.
3. Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 2011; 17: 3075-81.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
6. Geraud C, Schledzewski K, Demory A, et al. Liver sinusoidal endothelium: a microenvironment-dependent differentiation program in rat including the novel junctional protein liver endothelial differentiation-associated protein-1. Hepatology 2010; 52: 313-26.
7. Geraud C, Evdokimov K, Straub BK, et al. Unique cell type-specific junctional complexes in vascular endothelium of human and rat liver sinusoids. PLoS ONE 2012; 7: e34206.
8. Fernandez M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-20.
9. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41: 864-80.
10. Lencioni R, Cioni D, Della Pina C, Crocetti L, Bartolozzi C. Imaging diagnosis. Semin Liver Dis 2005; 25: 162-70.
11. Sanz-Cameno P, Trapero-Marugan M, Chaparro M, Jones EA, Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol; 2010: 272170.
12. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal 'capillarization' in dysplastic nodules of the liver. Am J Surg Pathol 1998; 22: 656-62.
13. Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999; 30: 1174-8.
14. Heukamp LC, Fischer HP, Schirmacher P, et al. Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions. Histopathology 2006; 49: 242-7.
15. Chen X, Higgins J, Cheung ST, et al. Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol 2004; 17: 1198-210.
16. Jia JH, Wang JY, Teh M, et al. Identification of proteins differentially expressed between capillary endothelial cells of hepatocellular carcinoma and normal liver in an orthotopic rat tumor model using 2-D DIGE. Proteomics 2010; 10: 224-34.
17. Nakamura S, Muro H, Suzuki S, et al. Immunohistochemical studies on endothelial cell phenotype in hepatocellular carcinoma. Hepatology 1997; 26: 407-15.
18. Carreira CM, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001; 61: 8079-84.
19. Llovet JM, Chen YB, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-67.
20. Cooley LS, Handsley MM, Zhou Z, et al. Reversible transdifferentiation of blood vascular endothelial cells to a lymphatic-like phenotype in vitro. J Cell Sci 2010; 123: 3808-16.
21. Dudley AC, Khan ZA, Shih SC, et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell 2008; 14: 201-11.
22. Lipton BH, Bensch KG, Karasek MA. Microvessel endothelial cell transdifferentiation: phenotypic characterization. Differentiation 1991; 46: 117-33.
23. Schledzewski K, Geraud C, Arnold B, et al. Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. J Clin Invest 2011; 121: 703-14.
24. Stahl S, Sacher T, Bechtold A, et al. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunol Lett 2009; 123: 31-7.
25. Kzhyshkowska J, Gratchev A, Schmuttermaier C, et al. Alternatively activated macrophages regulate extracellular levels of the hormone placental lactogen via receptor-mediated uptake and transcytosis. J Immunol 2008; 180: 3028-37.
26. Falkowski M, Schledzewski K, Hansen B, Goerdt S. Expression of stabilin-2, a novel fasciclin-like hyaluronan receptor protein, in murine sinusoidal endothelia, avascular tissues, and at solid/liquid interfaces. Histochem Cell Biol 2003; 120: 361-9.
27. Singer S, Ehemann V, Brauckhoff A, et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007; 46: 759-68.
28. Ryschich E, Lizdenis P, Ittrich C, et al. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 2006; 66: 198-211.
29. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006; 5: 1779-87.
30. Kzhyshkowska J, Mamidi S, Gratchev A, et al. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 2006; 107: 3221-8.
31. Park SY, Jung MY, Lee SJ, et al. Stabilin-1 mediates phosphatidylserine-dependent clearance of cell corpses in alternatively activated macrophages. J Cell Sci 2009; 122: 3365-73.
32. Schledzewski K, Falkowski M, Moldenhauer G, et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol 2006; 209: 67-77.
33. David C, Nance JP, Hubbard J, et al. Stabilin-1 expression in tumor associated macrophages. Brain Res 2012; 1481: 71-8.
34. Colombat M, Paradis V, Bieche I, et al. Quantitative RT-PCR in cirrhotic nodules reveals gene expression changes associated with liver carcinogenesis. J Pathol 2003; 201: 260-7.
35. Dieterich LC, Mellberg S, Langenkamp E, et al. Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFbeta2 in vascular abnormalization. J Pathol 2012; 228: 378-90.
36. Bartha K, Rieger H. Vascular network remodeling via vessel cooption, regression and growth in tumors. J Theor Biol 2006; 241: 903-18.
37. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
38. Stroka D, Trochsler M, Hlushchuk R, et al. Sinusoidal duplication by intussusception is an early event in liver regeneration after parial hepatectomy. J Hepatol 2007; 46: S146-S46.
39. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007; 46: 840-8.
40. Piguet AC, Saar B, Hlushchuk R, et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 2011; 10: 1007-17.
41. Hlushchuk R, Riesterer O, Baum O, et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol 2008; 173: 1173-85.
42. Monnier J, Boissan M, L'Helgoualc'h A, et al. CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer 2012; 48: 138-48.
43. Yu DC, Chen J, Ding YT. Hypoxic and highly angiogenic non-tumor tissues surrounding hepatocellular carcinoma: the 'Niche' of endothelial progenitor cells. Int J Mol Sci 2010; 11: 2901-9.
44. Heindryckx F, Mertens K, Charette N, et al. Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer 2010; 9: 219.
45. Benetti A, Berenzi A, Gambarotti M, et al. Transforming Growth Factor-beta 1 and CD105 Promote the Migration of Hepatocellular Carcinoma-Derived Endothelium. Cancer Res 2008; 68: 8626-34.
46. Morinaga S, Yamamoto Y, Noguchi Y, et al. Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver. Hepatogastroenterology 2003; 50: 1521-6.
47. Li H, Ge C, Zhao F, et al. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin beta1 signaling in human hepatocellular carcinoma. Hepatology 2011; 54: 910-9.
48. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-39.
49. Sironen RK, Tammi M, Tammi R, et al. Hyaluronan in human malignancies. Exp Cell Res 2011; 317: 383-91.
50. Gao CJ, Guo HT, Downey L, et al. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 2003; 24: 1871-8.
51. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-67.
52. Jung MY, Park SY, Kim IS. Stabilin-2 is involved in lymphocyte adhesion to the hepatic sinusoidal endothelium via the interaction with alpha M beta 2 integrin. J Leukoc Biol 2007; 82: 1156-65.
53. Kim S, Park SY, Kim SY, et al. Crosstalk between engulfment receptors stabilin-2 and integrin alpha v beta 5 orchestrates engulfment of phosphatidylserine-exposed erythrocytes. Mol Cell Biol 2012; 32: 2698-708.
54. Tang J, Wu YM, Zhao P, Jiang JL, Chen ZN. Betaig-h3 interacts with alpha3beta1 integrin to promote adhesion and migration of human hepatoma cells. Exp Biol Med (Maywood) 2009; 234: 35-9.
55. Jung CW, Song TJ, Lee KO, et al. Characterization of hepatocellular carcinoma cell lines based on cell adhesion molecules. Int J Mol Med 2012; 29: 1158-64.
56. Wu YH, Qiao XJ, Qiao SY, Yu L. Targeting integrins in hepatocellular carcinoma. Expert Opin Ther Targets 2011; 15: 421-37.
57. von Sengbusch A, Gassmann P, Fisch KM, et al. Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids. Am J Pathol 2005; 166: 585-96.
58. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-26.
59. Toso C, Mentha Gs, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 2011; 11: 2031-5.